Ribociclib trials for Hormone-receptor-positive Breast Cancer

All Ribociclib trials · All Hormone-receptor-positive Breast Cancer trials

Phase breakdown

Recruiting trials studying Ribociclib for Hormone-receptor-positive Breast Cancer

• A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
  NCT05766410 · Phase: Phase 2 · Ages: 20 Years and older · Sex: Female · 2 locations
• Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
  NCT05452213 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · 52 locations
• Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
  NCT06805812 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
  NCT05467891 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations

Common questions

How many trials study Ribociclib for Hormone-receptor-positive Breast Cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.